


Nano Plore

INTERIM MANAGEMENT'S DISCUSSION AND ANALYSIS

For the three-month periods ended September 30, 2022 and 2021





[Unless specified otherwise, all amounts are expressed in Canadian dollars]

This interim Management's discussion and analysis ("MD&A") provides a review of NanoXplore Inc.'s operations, performance and financial position for the three-month periods ended September 30, 2022 and 2021 and should be read in conjunction with the unaudited consolidated financial statements for the three periods ended September 30, 2022 and 2021 and with the audited consolidated financial statements for the years ended June 30, 2022 and 2021. The purpose of this document is to provide information on our activities. The information contained herein is dated as of November 14, 2022, date on which the MD&A was approved by the Corporation's board of directors. You will find more information about us on NanoXplore's website at www.nanoxplore.ca and on SEDAR at www.sedar.com, including all press releases.

The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to the preparation of interim financial statements including IAS 34, Interim Financial Reporting. The Corporation has consistently applied the accounting policies used in the preparation of its IFRS financial statements, including the comparative figures. We occasionally refer to non-IFRS financial measures in the MD&A. See the Non-IFRS measures section for more information. The terms "we", "our", "us", "NanoXplore" or the "Corporation" mean NanoXplore Inc. and its subsidiaries, unless otherwise indicated.


"Q1-2023" and "Q1-2022" refer to the three-month periods ended September 30, 2022 and 2021 respectively.

1. FORWARD-LOOKING STATEMENTS

This MD&A contains certain forward-looking statements within the meaning of applicable Canadian securities laws with respect to the Corporation. Such forward-looking statements are dependent upon a certain number of factors and are subject to risks and uncertainties. Actual results may differ from those expected. The Corporation considers the assumptions on which these forward-looking statements are based to be reasonable, but it advises the reader that these assumptions with regard to future events, many of which are beyond the Corporation's control, could prove incorrect as they are subject to risks and uncertainties inherent in the Corporation's activities. Management does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information of future events, except when required by the regulatory authorities.

This MD&A contains forward-looking statements. When used in this MD&A, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "project", "expect" and similar expressions are intended to identify forward-looking statements. In particular, this MD&A contains forward-looking statements with respect to, among other things, business objectives, expected growth, results of operations, performance, business projects and opportunities and financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such statements reflect NanoXplore's then current views with respect to future events based on certain facts and assumptions and are subject to certain risks and uncertainties, including without limitation changes in the risk factors described under the section "*Risks and Uncertainties*" of this MD&A. The forward-looking statements are based on certain key expectations and assumptions made by NanoXplore, including expectations and assumptions concerning availability of capital resources, business performance, market conditions and customer demand. Although NanoXplore believes that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements since no assurance can be given that they will prove to be correct.

Many factors could cause NanoXplore's actual results, performance or achievements to vary from those described in this MD&A, including without limitation those listed above, those described under the section "*Risks and Uncertainties*" of this MD&A as well as the assumptions upon which they are based proving incorrect. These factors should not be construed as exhaustive. Should one or more of these risks or uncertainties materialize, or should assumptions underlying forward-looking statements prove incorrect, actual results may vary materially from those described in this MD&A as intended, planned, anticipated, believed, sought, proposed, estimated or expected, and such forward-looking statements should not be unduly relied upon. NanoXplore does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. The forward-looking statements contained in this MD&A are expressly qualified by these cautionary statements. Forward-looking statements contained in this MD&A about prospective results of operations, financial position or cash flows are based on assumptions about future events, including economic conditions and proposed courses of action, based on NanoXplore's management's assessment of the relevant information currently available. Readers are cautioned that outlook information contained in this MD&A should not be used for the purposes other than for which it is disclosed herein or therein, as the case may be.



2. BUSINESS OVERVIEW

CORPORATION OVERVIEW

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in transportation and industrial markets. Also, the Corporation provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. The Corporation was formed by amalgamation under the *Canada Business Corporations Act* by Certificate of Amalgamation dated September 21, 2017 and is headquartered at 4500 Thimens Blvd, Montreal, QC, Canada.

On July 15, 2021, NanoXplore Inc. graduated from the Toronto Stock Exchange ("TSX") Venture Exchange to the TSX. NanoXplore is traded under "GRA" on the TSX and is also listed on the OTCQX and traded under "NNXPF".

The Corporation has the following subsidiaries:

- NanoXplore Switzerland Holding SA ("NanoXplore Switzerland"), based in Switzerland, with an equity interest of 100% [2021 – 100%]. NanoXplore Switzerland holds 100% of CEBO Injections SA ("CEBO").
- NanoXplore Holdings USA, Inc. ("NanoXplore Holdings USA"), based in the United States, with an equity interest of 100% [2021 – 100%]. NanoXplore Holdings USA holds 100% of NanoXplore USA, Inc.
- Sigma Industries Inc. ("Sigma"), based in Canada, with an equity interest of 100% [2021 – 100%]. Sigma has two active wholly owned subsidiaries; Faroex Ltd., based in Manitoba, and Rene Composite Materials Ltd., based in Quebec. Rene Composite Materials Ltd. has one active wholly owned subsidiary; RMC Advanced Technologies Inc., based in the United States.
- Canuck Compounders Inc. ("Canuck"), based in Canada, with an equity interest of 100% [2021 – nil].

KEY FINANCIAL HIGHLIGHTS

- Revenues from customers for Q1-2023 and Q1-2022 were \$27,147,167 and \$17,830,017, representing 52% increase;
- Gross margin on revenues from customers improved from 3.0% in Q1-2022 to 11.6% in Q1-2023;
- Adjusted EBITDA⁽¹⁾ improved from -\$3,760,406 in Q1-2022 to -\$1,977,032 in Q1-2023;
- Total liquidity of \$49,078,824 as at September 30, 2022, including cash and cash equivalents of \$42,774,905;
- Total long-term debt of \$9,025,338 as at September 30, 2022.


BUSINESS HIGHLIGHTS

During the three-month period ended September 30, 2022, the Corporation continued to focus on developing markets for its graphene production facility in Montreal, Canada and to develop down stream pre-mixed additives and products that facilitate such introduction. The Corporation has been successful in integration of GrapheneBlack in a few streams of products, both internally and externally, some of which has been press released during the year. The Corporation continues its engagement with many potential customers that are currently validating GrapheneBlack and GrapheneBlack improved masterbatches, concentrates, and products.

Macroeconomics and Supply chain issues

The COVID-19 pandemic and its negative collateral effects on the supply of materials and the availability of labour continued to have an adverse effect on our business, results of operations, cash flows and financial position, which is further exacerbated by the recent conflict between Russia and Ukraine. However, the full impact cannot be determined at this time. The extent of the impact will depend on various factors, including the possibility of future shutdowns, the potential for a recession in key markets due to the effect of the pandemic or other pandemics or other economic factors, and on the resulting impact on customers and suppliers, such as inflationary cost increases for wages, materials, energy, and other costs, any supply chain disruptions. A material deterioration in any of the foregoing could have a material adverse effect on the Corporation's business and results of operations. The Corporation expects to be able to continue to respond to the COVID-19 pandemic, and supply chain issues in a measured, prudent and decisive manner with continued emphasis on health and safety, cash conservation and the maintenance of its liquidity position.

⁽¹⁾ Adjusted EBITDA is a non-IFRS measure and that the reconciliation can be found in the section "Overall Results"



S&P/TSX Small Cap Index Inclusion

On September 16, 2022, after the close of trading, the Corporation was added to the S&P/TSX Small Cap index as part of the semi-annual rebalancing.

Purchase of assets of XG Sciences Inc.

On August 25, 2022, the Corporation purchased a significant portion of the assets of XG Sciences Inc. ("XG or XG Sciences") for an amount of US\$3,000,000 in a sale conducted by XG's senior secured creditor pursuant to Article 9 of Michigan's enactment of the Uniform Commercial Code. The Corporation and the senior creditor entered into an asset purchase agreement pursuant to which the Corporation acquired XG's mechanical milling platform, research and development lab and all issued and pending patents and trademarks, among other items.

XG Sciences specialized in the production of graphene nanoplatelets and the formulations of advanced materials that amplify product performance across diverse applications such as Lithium-ion battery anode materials, automotive, packaging, composites, concrete, and other industrial markets. XG Sciences ceased operations in July. While operating, XG Sciences worked with leading companies such as Ford for noise reduction and light-weighting using graphene-enhanced PU foam as well as Callaway Golf Corporation for graphene-enhanced golf balls.

XG Sciences has a high-quality patent portfolio (including 40 issued and pending patents) in important end-markets and their additives have attractive features and performance in the battery anode material, particularly in next generation solid-state battery chemistries. As a result of the transaction, the Corporation now owns all patents and patent applications including a portfolio of 7 patents (6 issued and 1 pending) of silicon-graphene battery materials and all XG trademarks. This complements the Corporation's existing intellectual properties and know-how related to graphene and graphene-silicon composite materials for Li-ion batteries.


The Corporation has moved all the assets from Lansing, Michigan to Canada to establish a dedicated battery material R&D facility. Moreover, the Corporation plans to use these assets to build a silicon-graphene anode material facility with a production capacity of 100-200 tons per year during 2023.

Total liquidity

As at September 30, 2022, the Corporation had total liquidity of \$49,078,824, including cash and cash equivalents and availability under the Corporation's operating loans.

Long-term debt

The total long-term debt decreased from \$9,450,814 as at June 30, 2022 to \$9,025,338 as at September 30, 2022 for a variation of \$425,476. Repayment amounted to \$484,207 during Q1-2023.



3. OVERALL RESULTS

HIGHLIGHTS

The following tables set out certain highlights of the Corporation's performance for the three-month periods ended September 30, 2022 and 2021. Refer to the Corporation's consolidated financial statements for the three-month periods ended September 30, 2022 and 2021 for a detailed account of the Corporation's performance for the periods presented in the tables below.

	Q1-2023	Q1-2022	Variation	
	\$	\$	\$	%
Revenues	27,232,525	18,818,446	8,414,079	45%
Operating loss	(5,774,600)	(4,817,937)	(956,663)	20%
Loss	(5,924,072)	(4,730,631)	(1,193,441)	25%
Loss per share (Basic and diluted)	(0.04)	(0.03)		
Non-IFRS Measures				
Adjusted EBITDA *	(1,977,032)	(3,760,406)	1,783,374	(47%)


Results of operations may include certain unusual and other items which have been separately disclosed, where appropriate, in order to provide a clear assessment of the underlying Corporation results. In addition to IFRS measures, management uses non-IFRS measures in the Corporation's disclosures that it believes provide the most appropriate basis on which to evaluate the Corporation's results.

* NON-IFRS MEASURES

This MD&A was prepared using results and financial information determined under IFRS. However, the Corporation considers certain non-IFRS financial measures as useful additional information in measuring the financial performance and condition of the Corporation. These measures, which the Corporation believes are widely used by investors, securities analysts and other interested parties in evaluating the Corporation's performance, do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other publicly traded companies, nor should they be construed as an alternative to financial measures determined in accordance with IFRS. Non-IFRS measures include "Adjusted EBITDA".

The following table provides a reconciliation of IFRS "Loss" to Non-IFRS "Adjusted EBITDA" for the three-month periods ended September 30, 2022 and 2021.

	Q1-2023	Q1-2022
	\$	\$
Loss	(5,924,072)	(4,730,631)
Current and deferred income tax recovery	(217,611)	(43,402)
Net interest expenses	55,653	220,436
Share of loss of a joint venture	311,430	57,741
Gain (loss) on disposal of property, plant and equipment	—	(322,081)
Foreign exchange	1,614,040	82,524
Canada Emergency Wage Subsidy ("CEWS")	—	(798,641)
Share-based compensation expenses	222,832	171,941
Depreciation and amortization	1,960,696	1,601,707
Adjusted EBITDA	(1,977,032)	(3,760,406)



RESULTS OF OPERATIONS VARIANCE ANALYSIS – THREE-MONTH PERIODS

Revenues

	Q1-2023	Q1-2022	Variation	
	\$	\$	\$	%
Revenues from customers	27,147,167	17,830,017	9,317,150	52%
Other income	85,358	988,429	(903,071)	(91%)
Total revenues	27,232,525	18,818,446	8,414,079	45%

Revenues from customers increased from \$17,830,017 in Q1-2022 to \$27,147,167 in Q1-2023. This increase is mainly due to a positive product mix including graphene enhanced products, the acquisition of Canuck in December 2021 and price increases offset by lower fluctuating tooling revenues.

Other income decreased from \$988,429 in Q1-2022 to \$85,358 in Q1-2023. The decrease is explained by the end of the CEWS program set up by the Canadian Federal government to help businesses deal with the COVID-19 pandemic. The Corporation received nil under this program during Q1-2023 compared to \$798,641 in Q1-2022 as the program ended in October 2021.

Adjusted EBITDA

The adjusted EBITDA improved from -\$3,760,406 in Q1-2022 to -\$1,977,032 in Q1-2023. The variation is explained as follows:

- Gross margin on revenues from customers increased by \$2,624,033 compared to last year due to higher sales as describe above, improved productivity and cost control; and
- This was offset by higher administrative expenses (SG&A and R&D) of \$736,229 mainly due additional headcounts and higher wages, including higher accrued variable compensation.

Loss

The loss increased from \$4,730,631 in Q1-2022 to \$5,924,072 in Q1-2023. The variation is mainly explained as follows:


- A decrease of \$798,641 in government assistance received from the Canadian federal government through its CEWS program;
- Higher depreciation and amortization of \$358,989 due mainly to the acquisition of Canuck;
- Higher loss on foreign exchange on derivative contracts of \$2,131,179 as explained below; and
- This was offset by an increase in adjusted EBITDA of \$1,783,374 as explained above.

Foreign exchange

	Q1-2023	Q1-2022	Variation	
	\$	\$	\$	%
Foreign exchange from operations	(952,178)	(352,515)	(599,663)	170%
Foreign exchange on derivative contracts	2,566,218	435,039	2,131,179	490%
Total foreign exchange	1,614,040	82,524	1,531,516	1856%

The Corporation had a positive impact on foreign exchange from operations of \$952,178 in Q1-2023 and of \$352,515 in Q1-2022 due to the increase of the US rate at the end of each quarter.

The foreign exchange on derivative contracts is a non-realized loss of \$2,566,218 in Q1-2023 compared to \$435,039 in Q1-2022. The loss is due to a spike increase of the US rate to 1.3833 as of September 30, 2022 with a higher level of coverage over the next two years. Since September 30, 2022, the Canadian dollar has strengthened and with current level of contract, each 100 bps movement in the USD to CAD rate will be an impact of approximately \$400,000.



FINANCIAL OUTLOOK

For the year ending June 30, 2023, the Corporation is expecting total revenues of \$110 million.

SUMMARY OF QUARTERLY RESULTS

The table below presents selected financial data for the eight most recently reported quarters. This unaudited quarterly information has been prepared in accordance with IFRS.

		Revenues	Loss ⁽¹⁾	Basic and diluted	
		\$	\$	loss per share	
				\$	
Q1-2023	September 30, 2022	27,232,525	(5,924,072)	(0.04)	Note 1
Q4-2022	June 30, 2022	28,280,476	(2,708,675)	(0.02)	Note 2
Q3-2022	March 31, 2022	28,406,750	(4,516,108)	(0.03)	Note 3
Q2-2022	December 31, 2021	18,801,487	(3,585,180)	(0.02)	Note 4
Q1-2022	September 30, 2021	18,818,446	(4,730,631)	(0.03)	Note 5
Q4-2021	June 30, 2021	20,886,168	(4,437,041)	(0.03)	
Q3-2021	March 31, 2021	18,421,736	(3,873,781)	(0.03)	Note 6
Q2-2021	December 31, 2020	17,463,831	(3,403,581)	(0.02)	Note 7

Note 1 The loss was higher due to a negative impact of foreign exchange on derivative contracts, lower margin and higher administrative expenses.

Note 2 The loss was lower due to positive product mix, improved productivity and cost control.

Note 3 Higher revenues are mainly explained by positive product mix including graphene enhanced product, the acquisition of Canuck, price increase and new sales program.


Note 4 The loss was lower than usual given a gain on disposal of property, plant and equipment of \$1,601,271.

Note 5 The loss was higher than usual given less CEWS received and lower gross margin on total revenues due to increases in raw material and labour costs.

Note 6 Higher revenues are mainly explained by tooling revenues.

Note 7 The increase in revenues is explained by the business acquisition of the CSP Newton Plant, completed on September 11, 2020. The pandemic was still negatively impacting our revenues. We also received government assistance of \$944,112 from the Canadian federal government through its CEWS program. The loss was higher than usual given less CEWS received, a negative FX (USD/CAD) impact and higher selling, general and administrative expenses is explained by the addition of strategic new positions, the addition of the CSP Newton Plant and higher salary expenses.


⁽¹⁾ Since the initial net assets acquired from CSP Newton Plant were estimated and the valuation was completed during Q4-2021, the fair value of the property, plant and equipment has been increased by \$1,125,450 and this adjustment has been reflected retrospectively to the acquisition date as a gain on a bargain purchase in conformity with IFRS 3, *Business Combinations*.



4. FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES

CONSOLIDATED FINANCIAL POSITION

	As at September 30, 2022 \$	As at June 30, 2022 \$	Variation \$	Main reasons for significant variation
Assets				
Cash and cash equivalents	42,774,905	51,232,068	(8,457,163)	Refer to section Cash Flows
Accounts receivable and Contract asset	22,356,894	21,077,868	1,279,026	Timing of cash receipts
Inventory	18,220,808	17,507,812	712,996	Mainly due to an increase of raw materials levels to avoid potential material shortages
Investment in a joint venture	3,927,344	4,238,774	(311,430)	
Right-of-use assets	8,144,729	8,381,031	(236,302)	
Property, plant and equipment, and equipment deposits	56,071,712	54,329,195	1,742,517	Acquisition of the asset of XG Sciences
Intangible assets	8,714,495	7,256,340	1,458,155	Acquisition of the asset of XG Sciences
Goodwill	1,919,673	1,919,673	—	
Other assets	1,350,110	1,315,688	34,422	
Total assets	163,480,670	167,258,449	(3,777,779)	
Liabilities and Shareholders' Equity				
Liabilities				
Accounts payable, accrued liabilities and income taxes payable	18,422,962	17,029,869	1,393,093	Mainly due to negative position of derivative contracts, offset by timing in payment
Contract liability	837,121	536,060	301,061	
Operating loans	5,897,480	4,648,900	1,248,580	To support higher working capital needs
Defined benefit liabilities	352,720	296,817	55,903	
Balance of purchase price of business acquisition	963,213	956,014	7,199	
Lease liability	14,941,816	15,232,915	(291,099)	
Long-term debt	9,025,338	9,450,814	(425,476)	
Deferred taxes liabilities	1,258,510	1,575,665	(317,155)	
Total liabilities	51,699,160	49,727,054	1,972,106	
Shareholders' Equity				
Share capital	169,586,592	169,354,272	232,320	
Reserve	4,334,097	4,185,185	148,912	
Foreign currency translation reserve	(150,731)	12,070	(162,801)	
Deficit	(61,988,448)	(56,020,132)	(5,968,316)	
Total shareholders' equity	111,781,510	117,531,395	(5,749,885)	
Total liabilities and shareholders' equity	163,480,670	167,258,449	(3,777,779)	



CASH FLOWS

	Q1-2023 \$	Q1-2022 \$	Variation	
			\$	%
Cash used in operating activities prior to changes in non-cash working capital items	(1,550,221)	(2,756,078)	1,205,857	(44%)
Changes in non-cash working capital items	(2,580,502)	(4,196,835)	1,616,333	(39%)
Operating activities	(4,130,723)	(6,952,913)	2,822,190	(41%)
Financing activities	85,312	(688,026)	773,338	(112%)
Investing activities	(4,433,538)	584,092	(5,017,630)	(859%)
Net effect of currency exchange rate on cash and cash equivalents	21,786	19,907	1,879	9%
Net change in cash and cash equivalents	(8,457,163)	(7,036,940)	(1,420,223)	20%

Operating activities

Cash flows used in operating activities prior to changes in non-cash working capital items were \$1,550,221 in Q1-2023 compared to \$2,756,078 in Q1-2022. The variation is mainly explained by an improvement of the adjusted EBITDA of \$1,783,374 offset by a reduction of \$798,641 in the amount received from the CEWS program.

Changes in non-cash working capital items amounted to -\$2,580,502 in Q1-2023, which is explained as follows:

- A decrease of accounts payable and accrued liabilities of \$1,235,130 due to payment of variable compensation and timing in payment; and
- An increase in accounts receivable and contract asset of \$1,055,990 is mainly due to timing in cash receipts.

Financing activities


Cash flows generated in financing activities were \$85,312 in Q1-2023 compared to cash flows used of \$688,026 in Q1-2022. In Q1-2023, the operating loans increased by \$1,200,000 and stock options were exercised for proceeds of \$158,400. These cash inflows were offset by an \$1,273,088 repayment on long-term debt and lease liability.

In Q1-2022, repayment of \$3,154,354 was completed on long-term debt and lease liability, which included advance debt payment of \$1,948,398. This was offset by lease incentive received of \$1,253,921, by an increase of \$1,000,000 on operating loans and by stock options exercised for proceeds of \$212,407.

Investing activities

Cash flows used in investing activities were \$4,433,538 in Q1-2023 compared to cash flows generated of \$584,092 in Q1-2022. In Q1-2023, the Corporation paid \$4,633,538 for capital expenditures which are mainly related to the acquisition of the assets of XG Sciences.

In Q1-2022, the Corporation sold two buildings for an amount of \$5,325,052, which was offset by a payment of \$2,051,304 for the balance of purchase price of the assets of CSP Newton Plant, and a payment of \$2,567,154 for capital expenditures which are mostly related to expenditures of composites equipment.



USE OF PROCEEDS

Use of Proceeds Reconciliation

i) February 2021

On February 12, 2021, the Corporation raised gross proceeds of \$46,000,000 by issuing a total of 11,500,000 Common Shares pursuant to a short form prospectus offering (the "February 2021 Offering"). The net proceeds of the February 2021 Offering were \$43,382,567, after deduction of underwriters' fees and other expenses.

The net proceeds of the February 2021 Offering are expected to be used by the Corporation within 24 months following the closing of the February 2021 Offering, as follows.

	Use of proceeds as described in the Short Form Prospectus dated February 5, 2021	Revised estimate of the use of proceeds as of the date hereof
Battery initiatives	4,000,000	5,000,000
Sales and marketing of graphene	20,000,000	20,000,000
Debt reduction	15,000,000	15,000,000
General corporate purposes	4,320,000	3,320,000
Total	43,320,000	43,320,000

The increase in planned expenditure for battery initiatives is mainly explained by higher-than-expected costs of equipment.

With respect to the reduction of the Corporation's debt, the Corporation expects to continue to gradually reduce its debt obligations, to provide a fertile ecosystem for growth. The Corporation is aware of the potential early payment fees resulting from repayment of debt before maturity and will take a balanced approach to minimize such fees.

With respect to the potential negative economic impacts of the COVID-19 pandemic on our business, the Corporation will continue to respond in a measured, prudent and decisive manner with continued emphasis on health and safety, cash conservation and the maintenance of its liquidity position.


The Corporation had negative cash flows from operating activities for the year ended June 30, 2022 and for the three-month period ended September 30, 2022. The Corporation cannot guarantee if it will have positive or negative cash flow from operating activities in future periods. To the extent that the Corporation has negative cash flows in any future period, certain of the proceeds from the February 2021 Offering or future offerings may be used to fund such negative cash flows from operating activities.

ii) February 2022

On February 24, 2022, the Corporation raised gross proceeds of \$30,001,200 by issuing a total of 6,522,000 Common Shares pursuant to a short form prospectus offering (the "February 2022 Offering"). The net proceeds of the February 2022 Offering were \$27,996,232, after deduction of underwriters' fees and other expenses.

The net proceeds of the February 2022 Offering are expected to be used by the Corporation within 24 months following the closing of the February 2022 Offering, as follows.

	Use of proceeds as described in the Short Form Prospectus dated February 24, 2022	Revised estimate of the use of proceeds as of the date hereof
Acquisition of assets or companies, partnerships and General corporate purposes	27,996,232	27,996,232
Total	27,996,232	27,996,232



LIQUIDITY AND CAPITAL RESOURCES

Throughout the COVID-19 pandemic, the Corporation has taken controlled and measured actions to preserve liquidity, including flexing and reducing its cost base, eliminating discretionary spending across its global footprint and delaying capital spending where and when appropriate. In addition, the Corporation enhanced its liquidity position with public financing for net proceeds of \$27,996,232 during the financial year 2022. As at September 30, 2022, the Corporation had total liquidity of \$49,078,824, including cash and cash equivalents and availability under the Corporation's operating loans.

Management believes that the Corporation has sufficient funds to meet its obligations, operating expenses and some development expenditures for the ensuing 12 months as they fall due. The Corporation's ability to continue its development activities is dependent on the impact of COVID-19, supply chain issues and the speed of introduction of graphene products into different industries. Although graphene products have generated revenues, the graphene commercial activity is still in the commercial introduction stage and, as a result, the Corporation could be dependent on external financing to fund its continued development program, if the commercial introduction of the graphene is delayed. The Corporation's main sources of funding have been the issuance of equity securities for cash, debt, cash flow from operations and funds from the government of Quebec with respect to R&D tax credits and other programs, such as Sustainable Development Technology Canada ("SDTC").

OFF-BALANCE SHEET ARRANGEMENTS

As of the date of this MD&A, the Company did not have any off-balance sheet arrangements, except for the commitment disclosed in the unaudited condensed interim consolidated financial statements for the three-month periods ended September 30, 2022 and 2021.

Management believes that the Company will be able to meet its obligations with cash on hand, cash flows from operations and drawdowns under existing credit facilities.

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

For a detailed description of the financial instruments and risk management associated with the Corporation and its activities, please refer to the consolidated financial statements for the years ended June 30, 2022 and 2021. These identified financial instruments and risks are consistent through the periods.

OUTSTANDING SHARES

As at November 11, 2022, the Corporation has:

- 165,575,525 common shares issued and outstanding;
- 3,232,500 options outstanding with expiry dates ranging between December 19, 2023 and August 4, 2027 with exercise prices between \$1.22 and \$6.44. If all the options were exercised, 3,232,500 shares would be issued for cash proceeds of \$7,435,300.


5. RELATED PARTY TRANSACTIONS

For a detailed description of all related party transactions, please refer to the note 7 "Related party transactions" in the unaudited condensed interim consolidated financial statements for the three-month periods ended September 30, 2022 and 2021.

6. RISKS AND UNCERTAINTIES

The operations of the Company are speculative due to the high-risk nature of its business, which is the acquisition, financing, technology and manufacturing. These risk factors could materially affect the Company's future operating results and could cause actual events to differ materially from those described in forward-looking information relating to the Company.

For a detailed description of risks and uncertainties, refer to the annual management's discussion and analysis for the years ended June 30, 2022 and 2021.



7. ACCOUNTING POLICIES

CRITICAL ACCOUNTING JUDGMENTS AND ESTIMATES

The preparation of consolidated financial statements requires management to make estimates and judgments about the future. Management periodically reviews these estimates, which are based on historical experience, changes in the business environment and other factors, including expectations of future events, that management considers reasonable under the circumstances. The estimates involve judgments we make based on the information available. However, accounting estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in future periods.

The Corporation based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. However, existing circumstances and assumptions about future developments may change due to market events or to circumstances beyond the Corporation's control. Such changes are reflected in the assumptions when they occur. This discussion addresses only those estimates that we consider important based on the degree of uncertainty and the likelihood of a material impact if we had used different estimates. There are many other areas in which we use estimates about uncertain matters.

For a detailed description of the critical accounting judgments and estimates associated with the Corporation and its activities, please refer to the section "Significant management estimates and judgments in applying accounting policies" in the note 2 in the consolidated financial statements for the years ended June 30, 2022 and 2021. The Corporation was not required to make significant judgments, estimates and assumptions in areas other than those mentioned in the consolidated financial statements for the years ended June 30, 2022 and 2021.

FUTURE CHANGES IN ACCOUNTING POLICIES

Certain standards and amendments to existing standards have been published, and their adoption is mandatory for future accounting periods. Refer to the note 3 in the consolidated financial statements for the years ended June 30, 2022 and 2021 and to the note 2 in the unaudited condensed interim consolidated financial statements for the three-month periods ended September 30, 2022 and 2021 for the details of these standards and amendments.

8. CONTROLS AND PROCEDURES

In accordance with National Instrument 52-109 of the Canadian Securities Authorities, the Corporation has filed certificates signed by the Chief Executive Officer and the Chief Financial Officer that, among other things, attest to the design of the disclosure controls and procedures ("DC&P") and the design and effectiveness of internal controls over financial reporting.

No changes were made to the Corporation's internal controls over financial reporting during Q1-2023 that have materially affected, or are reasonably likely to materially affect, internal controls over financial reporting.

Limitation on Scope of Design

The scope of design of internal controls over financial reporting and DC&P excluded the controls, policies, and procedures of Canuck, which was acquired on December 15, 2021. Canuck's contributions to the Corporation's consolidated statements of loss and comprehensive loss for the three-month period ended September 30, 2022 was approximately 28% of total revenues. Additionally, as at September 30, 2022, Canuck's assets and liabilities represented approximately 7% and 11%, respectively, of the Corporation's consolidated assets and liabilities. The amounts recognized for the net assets acquired as at the date of this acquisition are described in Note 3 of the unaudited condensed interim consolidated financial statements for the three-month periods ended September 30, 2022 and 2021.